The Mirage microfiber sirolimus eluting coronary scaffold

Bioresorbable scaffolds (BRSs) may potentially overcome the many pitfalls related to drug eluting stents (DESs). Following CE mark approval, the rapid adoption of this novel treatment has led to its use in all comers with complex lesion morphology even without randomized comparison with the DESs. The only published randomized clinical study thus far is the ABSORB II. However, the current generation (ABBOTT Bioresorbable Vascular Scaffold, BVS™) still has a lot of limitations. The Mirage Microfiber Sirolimus Eluting Coronary Scaffold (MMSES™, Manli Cardiology™) is designed to address the concerns of BVSs, such as improved vessel wall conformability, reduced strut protrusion into lumen, fracture resistance allowing rapid deployment until rated burst pressure, excellent deliverability, faster degradation time, ability to store at ambient room temperature <25°C, and no restriction on size availability. In contrast to the BVSs, the MMSES struts are round and thinner with less protrusion into the lumen. This streamlined geometry results in lesser activation of coagulation cascade and better promotion of endothelialization. This feature is interesting, especially in view of recent reports of somewhat higher BVSs thrombosis as compared to DESs.